Aquagenic Pruritus: First Manifestation of Polycythemia Vera
DOI:
https://doi.org/10.17140/DRMTOJ-1-102Keywords:
Aquagenic pruritus, Polycythemia vera, JAK inhibitorsAbstract
Aquagenic Pruritus (AP) can be a first symptom of systemic disease; especially strong
correlation with myeloproliferative disorders was described. In Polycythemia Vera (PV) patients
its prevalence varies from 31% to 69%. In almost half of the cases AP precedes the
diagnosis of PV and has significant influence on sufferers’ quality of life. Due to the lack of
the insight in pathogenesis of AP the treatment is still largely experiential. However, the new
JAK1/2 inhibitors showed promising results in management of AP among PV patients.
References
Diehn F, Tefferi A. Pruritus in polycythaemia vera: preva-lence, laboratory correlates and management. Br J Haematol. 2001; 115: e619-e621. doi: 10.1046/j.1365-2141.2001.03161.x
Chim CS, Kwong YL, Chan PT, Liang R. Polycythemia vera in Chinesepatients: thirty-six years of experience. Am J Hematol. 1997; 56: e59-e62. doi: 10.1002/(SICI)1096- 8652(199709)56:1<59::AID-AJH12>3.0.CO;2-Y
Jackson N, Burt D, Crocker J, Boughton B. Skin mast cells in polycythaemiavera: relationship to the pathogenesis and treat-ment of pruritus. Br J Dermatol. 1987; 116: 21-29. doi: 10.1111/ j.1365-2133.1987.tb05787.x
Heitkemper T, Hofmann T, Phan NQ, Ständer S. Aquagenic pruritus: associated diseases and clinical pruritus characteristics. J Dtsch Dermatol Ges. 2010; 8: 797-804. doi: 10.1111/j.1610- 0387.2010.07463.x
Siegel FP, Tauscher J, Petrides PE. Aquagenic pruritus in polycythemia vera: Characteristics and influence on quality of life in 441 patients. Am J Hematol. 2013; 88: 665-669. doi: 10.1002/ajh.23474
Archer CB, Camp RD, Greaves MW. Polycythaemia vera can present with aquagenic pruritus. Lancet. 1988; 1(8600): 1451. doi: 10.1016/S0140-6736(88)92254-4
Saini, KS, Patnaik MM, Tefferi A. Polycythemia vera-associ-ated pruritus and its management. Eur J Clin Invest. 2010; 40: 828-834. doi: 10.1111/j.1365-2362.2010.02334.x
Handfield-Jones SE, Hills RJ, Ive FA, Greaves MW. Aqua-genic pruritus associated with juvenile xanthogranuloma. Clin Exp Dermatol. 1993; 18(3): 253-255. doi: 10.1111/j.1365- 2230.1993.tb02180.x
McGrath JA, Greaves MW. Aquagenic pruritus and myelo-dysplastic syndrome. Am J Hematol. 1991; 37(1): 63.
Khalifa N, Singer CR, Black AK. Aquagenic pruritus in a pa-tient associated with myelodysplasia and T-cell non-Hodgkin’s lymphoma. J Am Acad Dermatol. 2002; 46: 144-145.
Gregor M. Aquagenic pruritus and hepatitis. Internist (Berl). 1999; 40(2): 220-221.
Moreno Caballero B, Castro Barrio M, Blancho Andres C. Aquagenic pruritus due to use of bupropion [in Spanish]. Aten Primaria. 2002; 30: 662-663.
Liu M, Shinkai K. Reversible aquagenic pruritus associated with testosterone-induced erythrocytosis. J Am Acad Dermatol. 2014; 70: e139-e140. doi: 10.1016/j.jaad.2014.01.852
Newton JA, Singh AK, Greaves MW, Spry CJ. Aquagenic pruritus associated with the idiopathic hypereosinophilic syn-drome. Br J Dermatol. 1990; 112: 103-106. doi: 10.1111/j.1365- 2133.1990.tb08246.x
Bircher AJ, Meier-Ruge W. Aquagenic pruritus. Water-in-duced activation of acetylcholinesterase. Arch Dermatol. 1988; 124: 84-89. doi: 10.1001/archderm.1988.01670010048020
Gilbert HS, Warner RR, Wasserman LR. A study of hista-mine in myeloproliferative disease. Blood. 1966; 28: 795-806.
Abdel-Naser MB, Zaki MS, Mousa MH et al. Cutaneous mononuclear cells and eosinophils are significantly increased after warm water challenge in pruritic areas of polycythemia vera. J Cutan Pathol. 2007; 34: 924-929. doi: 10.1111/j.1600- 0560.2007.00927.x
Tefferi A, Lasho TL, Schwager SM, et al. The clinical pheno-type of wild-type, heterozygous, and homozygous JAK2V617F Dermatol Open J in polycythemia vera. Cancer. 2006; 3: 631-635. doi: 10.1002/ cncr.21645
Pieri L, Bogani C, Gugliemelli P, et al. The JAK2V617F mutation induces constitutive activation and agonist hypersensi-tivity in basophils from patients with PV. Haematologica. 2009; 94: 1537-1545. doi: 10.3324/haematol.2009.007047
Lengfelder E, Berger U, Hehlmann R. Interferon alpha in the treatment of polycythemia vera. Ann Hematol. 2000; 79: 103- 109.
Menage HD, Norris PG, Hawk JL, Graves MW. The effi-cacy of psoralen photochemotherapy in the treatment of aqua-genic pruritus. Br J Dermatol. 1993; 129: 163-165. doi: 10.1111/ j.1365-2133.1993.tb03520.x
Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood. 2002; 7: 2627. doi: 10.1182/blood.V99.7.2627
Verstovsek S, Passamonti F, Rambaldi A, et al. A Phase 2 Study of INCB018424, an oral, selective JAK1 ⁄ JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea. Blood. 2009; 114: 631. doi: 10.1002/cncr.28441
Pardanani AD. A Phase I evaluation of TG101348, a selec-tive JAK2 inhibitor, in myelofibrosis: clinical response is ac-companied by significant reduction in JAK2V617F allele burden ASH. Blood. 2009; 114: 755.
Vannucchi AM, Guglielmelli P, Gattoni E, et al. RAD001, an inhibitor of mTOR, shows clinical activity in a phase I ⁄ II study in patients with primary myelofibrosis (PMF) and post polycy-themia vera ⁄ essential thrombocythemia myelofibrosis (PPV ⁄ PET MF). Blood. 2009; 114: 307.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Dermatology (DER) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
